NCT06434103View on ClinicalTrials.gov

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

March 31, 2027

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
DRUG

SHR-A1921；Adebrelimab；SHR-8068；carboplatin

SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06434103 - Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC | Biotech Hunter | Biotech Hunter